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Abstract
Parkinson's disease (PD) is a progressive neurodegenerative disorder
affecting approximately 1–2% of the general population over age
60. It is characterized by a rather selective loss of dopaminergic
neurons in the substantia nigra and the presence of α-synuclein-
enriched Lewy body inclusions. Mutations in the Parkin gene
(PARK2) are the major cause of autosomal recessive early-onset
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parkinsonism. The Parkin protein is an E3 ubiquitin ligase with
various cellular functions, including the induction of mitophagy upon
mitochondrial depolarizaton, but the full repertoire of Parkin-binding
proteins remains poorly defined. Here we employed tandem affinity
purification interaction screens with subsequent mass spectrometry
to profile binding partners of Parkin. Using this approach for two
different cell types (HEK293T and SH-SY5Y neuronal cells), we
identified a total of 203 candidate Parkin-binding proteins. For the
candidate proteins and the proteins known to cause heritable forms
of parkinsonism, protein-protein interaction data were derived
from public databases, and the associated biological processes
and pathways were analyzed and compared. Functional similarity
between the candidates and the proteins involved in monogenic
parkinsonism was investigated, and additional confirmatory
evidence was obtained using published genetic interaction data
from Drosophila melanogaster. Based on the results of the different
analyses, a prioritization score was assigned to each candidate
Parkin-binding protein. Two of the top ranking candidates were
tested by co-immunoprecipitation, and interaction to Parkin was
confirmed for one of them. New candidates for involvement in cell
death processes, protein folding, the fission/fusion machinery, and
the mitophagy pathway were identified, which provide a resource for
further elucidating Parkin function.
Introduction
Parkinson's disease (PD) is a progressive neurodegenerative disorder
affecting approximately 1–2% of the general population over age 60
[1]. It is characterized clinically by tremor, rigidity, reduced motor
activity (bradykinesia), and postural instability [2] and pathologically
by loss of dopaminergic neurons in the substantia nigra pars compacta
and the presence of α-synuclein positive inclusions in the cytoplasm
of neurons, termed Lewy bodies [3], [4]. Most cases are idiopathic or
late-onset PD (>85% of all cases), whereas <10% of cases are familial
forms. The identification and characterization of genes that cause
heritable forms of the disease have provided important insights into
the pathways involved in dopaminergic neurodegeneration. Mutations
in the Parkin gene (PARK2) represent the most common known cause
of early-onset parkinsonism (10 to 20%) [5]. The Parkin protein is an
E3 ubiquitin ligase responsible for the transfer of activated ubiquitin
molecules to a protein substrate [6]. This ubiquitination process has
various functional consequences in addition to the protein degradation
by the 26S proteasome, including regulation of receptor trafficking,
cell cycle progression, gene transcription, DNA repair, and immune
responses [7].
Studies in Drosophila melanogaster revealed compelling evidence
for a role of Parkin in the maintenance of mitochondrial function [8].
Genetic interaction between Parkin and PINK1, mutations of which
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also cause early-onset parkinsonism, indicated that both genes are
acting in a common pathway. Loss of one of these two genes results
in mitochondrial pathology and muscle and dopaminergic neuron
degeneration. Overexpression of Parkin rescues the phenotypes caused
by PINK1 deficiency, but not vice versa, indicating that Parkin intervenes
downstream of PINK1 [9], [10]. In addition, genetic interactions between
Parkin and PINK1 and genes encoding components of the mitochondrial
fission/fusion machinery indicate an involvement of the PINK1/Parkin
pathway in the regulation of mitochondrial dynamics [11], [12].
Parkin is at steady state essentially cytosolic, and recent work has
shown that it selectively and rapidly translocates from the cytosol
to depolarized mitochondria with low membrane potential and
subsequently induces their autophagic removal in a process called
mitophagy [13]–[16].
Increasing our knowledge about the interactions between Parkin and
other cytoplasmic and mitochondrial proteins will provide further
biological insights into Parkin function and the intricate relationships
between the multiple roles of Parkin. The identification of such Parkin-
binding proteins may have a general role in the pathogenesis of PD and
elucidate novel therapeutic targets.
In this study, we report a comprehensive set of novel candidate Parkin-
binding proteins identified by Tandem Affinity Purification (TAP)/mass
spectrometry (MS) interaction screens. Following the established “guilt
by association” strategy, where proteins/genes are prioritized if they are
found to be related to known disease genes and processes [17]–[19], a
set of “seed” proteins known to be related to genetic parkinsonism was
used to prioritize the candidate Parkin-binding proteins. In particular,
this set of proteins provided the basis for the prioritization of candidate
proteins based on the known interactions to these proteins. In addition,
it was used in an analysis of PD-related pathways and processes and in
the prioritization of the candidate Parkin-binding proteins based on their
functional relationships. The candidate proteins were also compared to
complementary experimental data from genetic interaction screens in
Drosophila melanogaster and genome-wide association studies (GWAS)
in humans. Our study identified novel candidate Parkin-binding proteins
for involvement in cell death processes, protein folding and response
to unfolded protein, the fission/fusion machinery, and the mitophagy
pathway, and the combined results of the bioinformatics analyses were
used to prioritize them into different selection levels.
Results
Protein-protein interaction data for the candidate Parkin-binding
proteins obtained from the TAP experiments and the proteins known
to cause heritable forms of parkinsonism were derived from public
databases, and the respective biological processes and pathways were
analyzed and compared. Network models were applied to investigate
the functional relationships between the candidate Parkin-binding
proteins and the proteins related to monogenic parkinsonism. In
addition, the candidate dataset was compared to results from genetic
interaction screens in Drosophila and human GWAS. The candidate
proteins were prioritized into different selection levels, which were
compared to the results of an independent gene prioritization approach.
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Finally, two candidates were tested for interaction to Parkin by co-
immunoprecipitation.
TAP results and protein datasets
TAP-tagged Parkin containing protein complexes were purified in a
two-stage purification process of protein extracts prepared from whole
cell lysates and cytosolic and mitochondrial fractions from HEK293T
and SH-SY5Y cells and analyzed by MS. The TAP experiments resulted
in different protein datasets listed in Table 1 (ParkinTAP datasets). In
total, 203 unique peptides were identified as candidate Parkin-binding
proteins (Table 1; ParkinTAP candidates); approximately 50% of the
candidate proteins were identified in the mitochondrial fractions (Mito
dataset) and 50% in the cytosolic fractions (Cyto dataset), with an




Label Description Size ParkinTAP datasets WholeCellsNT-293T HEK293T, Not
Treated, Whole Cells 97 MitoNT-293T HEK293T, Not Treated, Mitochondrial
Fraction 65 CytoNT-293T HEK293T, Not Treated, Cytosolic Fraction 55 MitoT-293T
HEK293T, Treated, Mitochondrial Fraction 18 CytoT-293T HEK293T, Treated,
Cytosolic Fraction 22 MitoT-SH-SY5Y SH-SY5Y, Treated, Mitochondrial Fraction
54 CytoT-SH-SY5Y SH-SY5Y, Treated, Cytosolic Fraction 53 Combined datasets
ParkinTAP candidates Union of all ParkinTAP datasets: WholeCellsNT-293T,
MitoNT-293T, CytoNT-293T, MitoT-293T, CytoT-293T, MitoT-SH-SY5Y, CytoT-SH-
SY5Y 203 Mito Union of MitoNT-293T, MitoT-293T and MitoT-SH-SY5Y 99 Cyto
Union of CytoNT-293T, CytoT-293T and CytoT-SH-SY5Y 94 External datasets
MonogenicPD Proteins encoded by genes causing monogenic parkinsonism [20]
9 Pink1TAP PINK1-interacting candidates identified by TAP [21] 17 ParkinIP
Parkin interacting proteins from HNet 77 MonogenicPDIP Interacting partners
of MonogenicPD proteins from HNet 668 PINK1IP PINK1-interacting proteins
from HNet 44 RelatedPD Union of ParkinIP and MonogenicPD 80 Comparison
of datasets ParkinTAP ∩ ParkinIP Overlap between ParkinTAP candidates and
Parkin interactors in HNet 4(3) ParkinTAP ∩ MonogenicPD Overlap between
ParkinTAP candidates and MonogenicPD 1(0) ParkinTAP ∩ MonogenicPDIP
Overlap between ParkinTAP candidates and MonogenicPDIP 40(39) ParkinTAP ∩
Pink1TAP Overlap between ParkinTAP and Pink1TAP candidates 15(15) ParkinIP
∩ MonogenicPD Overlap between Parkin interactors in HNet and in MonogenicPD
6(5)
*. dataset intersection (∩).
**. in brackets: set size excluding Parkin.
In addition, the following datasets were used in the analyses:
MonogenicPD, which includes proteins encoded by genes implicated
in monogenic forms of parkinsonism [20], Pink1TAP, which provides
a list of candidate PINK1-interacting proteins identified in a previous
TAP study [21], and ParkinIP, PINK1IP, and MonogenicPDIP, which
include proteins known to interact with Parkin, PINK1, and proteins
from MonogenicPD, respectively. The dataset RelatedPD includes the
ParkinIP and MonogenicPD datasets. The previously reported Pink1TAP
dataset mostly overlaps with the ParkinTAP candidates of the present
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study, with the exception of PINK1 itself and CDC37 (cell division cycle
37 homolog). The database identifiers of the proteins present in each
dataset are provided in Table S1.
Protein-protein interactions
The protein interactions of Parkin and MonogenicPD were investigated
based on the human interactome network (HNet). We analyzed the
interaction network within the RelatedPD dataset, which includes 80
proteins and 206 binary interactions, out of 307 interactions in total.
Six of the nine MonogenicPD proteins are Parkin interactors in HNet
(ParkinIP ∩ MonogenicPD in Table 1), and only UCHL1, FBXO7, and
ATP13A2 from MonogenicPD do not interact directly with Parkin.
Nevertheless, UCHL1 and FBXO7 interact with ParkinIP proteins, and
therefore the RelatedPD subnetwork consists of a single connected
component when ATP13A2, which is responsible for Kufor-Rakeb
syndrome, a form of parkinsonism with dementia and juvenile disease
onset [22], is excluded.
We investigated also the interactions between the proteins in ParkinTAP,
and out of the 203 candidates, 193 are part of a single large connected
component, and only 10 do not interact with the other ParkinTAP
candidates (Table S2).
For each ParkinTAP candidate, the shortest path network distance (ND)
to Parkin and to MonogenicPD proteins was computed in SpNet, which
is a subnetwork of HNet, including the ParkinTAP candidates, ParkinIP,
MonogenicPD, MonogenicPDIP and all proteins in the interconnecting
shortest paths between ParkinTAP and MonogenicPD. In total, it
includes 4,009 proteins and 290,496 interactions, where most of the
interactions (268,484) are expanded complexes. Table 2 shows the ND
to Parkin and the minimum network distance to MonogenicPD proteins
for a selection of candidates, the results for all ParkinTAP candidates
are available in Table S3 (ND = 1 corresponds to direct interaction, ND
 = 2 indicates one intermediate in the shortest path). In this network,
only three ParkinTAP candidates are known Parkin-binding proteins
(DNAJA1, HSPA1A, HSPA8) [23], and 164 candidate proteins interact
with Parkin through one intermediate protein (Parkin ND = 2). In total,
40 candidates are MonogenicPDIP, and six of them interact with two
different MonogenicPD proteins (MonogenicPD #ND = 2). Most of the
interactions to MonogenicPD (28 of 40) include UCHL1, which was not
confirmed since first described in 1998 [24], and 25 of these involve a
large complex consisting of UCHL1 and 166 additional proteins [25]. Ten
ParkinTAP candidates interact with PARK7 (DJ-1), three interact with
SNCA, and one interacts with LRRK2 (Table 2; column iMonogenicPD).
Table 2
Object ID: 10.1371/journal.pone.0078648.t002
Summary of results for ParkinTAP candidates passing the first
seven selection levels.
Rank Entrez Gene ID HGNC Symbol Parkin ND MonogenicPD ND MonogenicPD
#ND iMonogenicPD Not Complex Pink1 TAP HNet Degree GOComp FunSim
MonogenicPD GOSlimPD ParkinGS Pink1GS CalmodulinIP Selection Level 1 5071
PARK2 0 0 1 PARK2 – – 76 true true – true true – 0 2 3301 DNAJA1 1 1 2 PARK2,
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UCHL1 – – 551 true – true true – true 0 3 3303 HSPA1A 1 1 2 PARK2, SNCA – true
926 – true true true true true 0 4 3312 HSPA8 1 1 2 PARK2, UCHL1 – true 1292
true – true true true true 0 5 5052 PRDX1 2 1 2 UCHL1, PARK7 – – 559 – – true
– – true 1 6 801 CALM1 2 1 2 UCHL1, SNCA – – 780 – – – true true true 1 7 3181
HNRNPA2B1 2 1 2 UCHL1, PARK7 – – 848 – – – – – true 1 8 10845 CLPX 2 1 1
PARK7 – – 161 true true – true true – 2 9 10951 CBX1 3 1 1 UCHL1 – – 235 – true
– true true – 2 10 3329 HSPD1 2 1 1 PARK7 – true 904 true true true true true true
2 11 60 ACTB 2 1 1 UCHL1 – – 1016 true true true true true true 2 12 492 ATP2B3
3 3 8 0 true – 2 – true true – – – 3 13 9868 TOMM70A 2 2 5 0 true – 8 true true true
– – – 3 14 490 ATP2B1 3 2 2 0 true – 8 – true true – – true 3 15 23581 CASP14
3 2 5 0 – – 29 – true true true – – 3 16 3005 H1F0 2 2 4 0 – – 74 – true true – –
true 3 17 7818 DAP3 2 2 7 0 – – 125 true true true – – – 3 18 5589 PRKCSH 2 2
5 0 – – 127 true true true true true true 3 19 84790 TUBA1C 2 1 1 UCHL1 – true
266 true – – true – true 3 20 9131 AIFM1 2 2 8 0 – – 333 – true true true true true
3 21 10128 LRPPRC 2 1 1 PARK7 – true 461 true – – true true – 3 22 213 ALB 2
1 1 UCHL1 – – 587 true – true – – true 3 23 10383 TUBB4B 2 1 1 UCHL1 – – 599
true – true – true true 3 24 7431 VIM 2 1 1 SNCA – – 635 – – true – – true 3 25
7277 TUBA4A 2 1 1 UCHL1 – – 733 true – true – – true 3 26 3326 HSP90AB1 2 1
1 LRRK2 – true 739 true – true – – true 3 27 3320 HSP90AA1 2 1 1 UCHL1 – true
757 true – true – – true 3 28 3313 HSPA9 2 1 1 UCHL1 – true 778 true – true true
true true 3 29 4869 NPM1 2 1 1 PARK7 – – 813 true – true – – true 3 30 203068
TUBB 2 1 1 UCHL1 – true 889 true – – – true true 3 31 3309 HSPA5 2 1 1 UCHL1
– true 921 true – true – – true 3 32 284110 GSDMA – – – 0 – – – – true true – – –
3 33 9939 RBM8A 2 1 1 UCHL1 – – 245 true – – true true – 4 34 813 CALU 2 1 1
UCHL1 – – 266 true – – true true true 4 35 5955 RCN2 2 1 1 UCHL1 – – 297 – –
– true true true 4 36 10240 MRPS31 2 1 1 PARK7 – – 365 – – – true true – 4 37
2597 GAPDH 2 1 1 UCHL1 – – 595 – – – true true true 4 38 5250 SLC25A3 2 1 1
UCHL1 – – 597 – – – true true true 4 39 498 ATP5A1 2 1 1 UCHL1 – – 611 true –
– true – true 4 40 3032 HADHB 2 1 1 UCHL1 – – 675 – – – – true true 4 41 1915
EEF1A1 2 1 1 UCHL1 – – 1079 – – – true true true 4 42 4747 NEFL 2 1 1 UCHL1 –
– 37 true – – – – – 5 43 84617 TUBB6 2 1 1 UCHL1 – – 174 true – – – – true 5 44
10165 SLC25A13 2 1 1 PARK7 – – 648 true – – – – true 5 45 221613 HIST1H2AA
3 2 1 0 true – 8 – true – – – – 6 46 539 ATP5O 2 2 6 0 – – 63 true true – true true
– 6 47 51081 MRPS7 2 2 6 0 – – 128 – true – true – – 6 48 6418 SET 2 2 7 0 – –
169 true true – true true – 6 49 4976 OPA1 2 2 6 0 – – 177 true true – true true true
6 50 4741 NEFM 2 1 1 UCHL1 – – 233 – – – – – true 6 51 11335 CBX3 2 2 5 0 – –
256 – true – true true – 6 52 1975 EIF4B 2 2 8 0 – – 300 – true – – – – 6 53 9532
BAG2 2 2 8 0 – – 351 true true – true true true 6 54 9092 SART1 2 1 1 PARK7 – –
376 – – – – – – 6 55 9551 ATP5J2 2 2 6 0 – – 379 true true – – – true 6 56 10627
MYL12A 2 1 1 PARK7 – – 385 – – – – – true 6 57 509 ATP5C1 2 2 7 0 – – 389 true
true – – – – 6 58 6224 RPS20 2 2 7 0 – – 390 – true – true – – 6 59 6137 RPL13 2
2 8 0 – – 436 – true – – – true 6 60 6128 RPL6 2 2 7 0 – – 468 – true – – – true 6 61
7203 CCT3 2 2 8 0 – – 598 true true – true true true 6 62 302 ANXA2 2 1 1 UCHL1
– – 811 – – – – – true 6 63 3185 HNRNPF 2 1 1 UCHL1 – – 928 – – – – – true 6 64
8363 HIST1H4J – – – 0 – – – – true – – – – 6 65 7171 TPM4 3 2 3 0 – – 12 – – true
– – – 7 66 4724 NDUFS4 3 2 3 0 – – 44 true – true – – – 7 67 9118 INA 2 2 6 0 – –
82 – – true – – – 7 68 3306 HSPA2 2 2 7 0 – true 95 true – true true – – 7 69 1153
CIRBP 2 2 4 0 – – 149 – – true – true – 7 70 8531 CSDA 2 2 7 0 – – 167 – – true
true true – 7 71 4001 LMNB1 2 2 7 0 – – 206 – – true true true – 7 72 291 SLC25A4
2 2 6 0 – – 227 true – true – – – 7 73 811 CALR 2 2 6 0 – – 235 true – true – – true
7 74 6182 MRPL12 2 2 5 0 – – 263 true – true – – true 7 75 27339 PRPF19 2 2 7
0 – – 275 – – true true – – 7 76 6421 SFPQ 2 2 7 0 – – 307 – – true true true – 7
77 7184 HSP90B1 2 2 7 0 – – 316 true – true – – true 7 78 5984 RFC4 2 2 6 0 – –
324 – – true – – true 7 79 2521 FUS 2 2 6 0 – – 354 – – true true true – 7 80 4720
Profiling of Parkin-Binding Partners 7
NDUFS2 2 2 8 0 – – 410 – – true true true true 7 81 6742 SSBP1 2 2 7 0 – – 531
true – true true true true 7 82 10642 IGF2BP1 2 2 8 0 – – 647 – – true – – – 7 83
3305 HSPA1L 2 2 8 0 – true 661 true – true true true true 7 84 708 C1QBP 2 2 7 0
– – 661 – – true true – true 7 85 2547 XRCC6 2 2 8 0 – – 813 – – true true true – 7
86 7531 YWHAE 2 2 8 0 – – 833 true – true – – true 7 87 8607 RUVBL1 2 2 8 0 –
– 858 – – true true – – 7 88 4000 LMNA 2 2 8 0 – – 871 true – true true true true 7
89 10856 RUVBL2 2 2 8 0 – – 960 true – true true – – 7 90 7425 VGF – – – 0 – – –
true – true – – – 7
Parkin ND: Shortest path network distance to Parkin in SpNet protein-
protein interaction network.
MonogenicPD ND: Minimum shortest path network distance to
MonogenicPD in SpNet.
MonogenicPD #ND: Number of shortest paths to MonogenicPD with
minimum value in SpNet.
iMonogenicPD: Gene symbols of interacting MonogenicPD.
Not Complex: No complex interaction with other ParkinTAP candidates.
Pink1TAP: Pink1TAP candidate.
HNet Degree: Number of protein interactions in iRefIndex.
GOComp: Logical OR of “true” values of six GOComparisons listed in
Table S3.
FunSim MonogenicPD: Functional similarity ≥0.7 to a MonogenicPD
protein.
GOSlimPD: Annotated to GOSlimPD or children term.
ParkinGS: Overlap with Parkin fly genetic screen.
Pink1GS: Overlap with PINK1 fly genetic screen.
CalmodulinIP: Interaction with calmodulin.
The network of the interacting partners of the ParkinTAP candidate
protein LRPPRC is visualized in Figure 1A as an example for a candidate
protein with many interactions. LRPPRC forms a complex with PARK7
(DJ-1), and the network is relatively dense with multiple complex




Direct protein interactions of two ParkinTAP candidates selected
as exemplary proteins: LRPPRC (A) and TOMM70A (B).
Proteins are represented as nodes and interactions as edges; the
edges are drawn as solid and dashed lines for binary and complex
interactions, respectively. Binary interactions to the selected candidates
are represented by thicker edges. ParkinTAP ND X are ParkinTAP
candidates at network distance X of MonogenicPD, where ParkinTAP
ND 1 are direct MonogenicPD interactors. A: LRPPRC. There are many
interactors of LRPPRC in iRefIndex, resulting in a dense network of
complex interactions. LRPPRC interacts with MonogenicPD PARK7, as
well as with 48 other ParkinTAP candidates, and the network includes
14 ParkinIP and 77 MonogenicPDIP. B: TOMM70A. Only eight proteins
interact directly with TOMM70A, including one ParkinTAP candidate
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(HSP90AA1), two ParkinIP (TOMM20, UBC) and one MonogenicPDIP
(VDAC1).
Another example is provided by the network of TOMM70A, which
is characterized by only few interactions (Figure 1B). It consists of
only eight nodes, including one ParkinTAP candidate as well as one
MonogenicPDIP and two ParkinIP proteins. Interaction networks for
additional candidate proteins (CLPX, PRKCSH, DAP3 and CALU) are
provided in Figures S1A-S1D.
Calmodulin (CALM1) is one of the candidate Parkin-binding proteins,
which interacts with two other MonogenicPD proteins (UCHL1, SNCA)
in HNet. However, CALM1 is a possible artifact, since Parkin was
tagged with a calmodulin binding peptide according to the TAP protocol.
Therefore, any ParkinTAP candidate that is a calmodulin interactor (96
from HNet) may also be a possible TAP artifact (Table 2 and Table S3;
column CalmodulinIP).
A total of 96 ParkinTAP candidates showed a significant DAPPLE score
(P<0.01) indicating a high connectivity between the ParkinTAP and
MonogenicPD datasets (Table S3).
Analysis of pathways and GO biological processes
related to PD
In order to identify the pathways and processes known to be involved in
the pathophysiology of PD and in particular Parkin-linked parkinsonism,
we performed enrichment analyses for the RelatedPD dataset, consisting
of ParkinIP and MonogenicPD. As expected, the most significant
pathways according to ConsensusPathDB were “Parkinson's disease” (P
 = 1.6×10−14), “Alpha-synuclein signaling” (P = 1.1×10−08), and “Role of
parkin in ubiquitin-proteasomal pathway” (P = 1.5×10−07) (Table S4).
The most significant GO (gene ontology) biological processes were
related to Parkin function in the ubiquitin-proteasome system: “protein
modification by small protein conjugation” (LEA P = 2.4x10−19) and
“protein ubiquitination” (LEA P = 1.9×10−17). Additional significant
processes were related to apoptosis and to mitochondrial and
neuronal processes: “cell death” (LEA P = 2.4×10−14), “regulation
of cell death” (LEA P = 1.2×10−10), “apoptosis” (LEA P = 6.6×10−10),
“mitochondrion organization” (LEA P = 1.4×10−9), “synaptic
transmission” (LEA P = 2.8×10−8), “neuron death” (LEA P = 7.7×10−8),
and “dopamine transport” (LEA P = 7.8×10−8) (Table S5).
Pathway analysis for ParkinTAP candidates
The most significantly enriched pathways in the dataset of the 203
ParkinTAP candidate proteins were related to gene expression, in
particular to RNA processing/splicing and translation: “Ribosome” (P
 = 2.3×10−15) and “Processing of Capped Intron-Containing Pre-
mRNA” (P = 6.0×10−15). Other enriched pathways relate to protein
folding, like “Prefoldin mediated transfer of substrate to CCT/TriC” (P =
 2.0×10−10) and “Protein folding” (P = 1.9×10−7), or to protein processing:
“Protein processing in endoplasmic reticulum” (P = 1.6×10−8). Pathway
enrichment analysis was also performed for the Mito and Cyto datasets
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separately. In the Mito dataset, the most significant pathways were
related to protein folding and oxidative phosphorylation, whereas
in the Cyto dataset the most enriched pathways were related to
gene expression. Detailed pathway enrichment results, including the
ParkinTAP candidate proteins for each enriched pathway, are provided in
Table S6.
Analysis of GO biological processes for ParkinTAP
candidates
Of the 203 ParkinTAP candidate proteins, 175 were annotated with a
GO biological process. The most well represented biological process
categories were related to RNA processing and translation, like
“translational elongation” (LEA P = 1.3×10−21) and “nuclear mRNA
splicing, via spliceosome” (LEA P = 1.1×10−19). Several processes
related to protein folding and complex assembly were also significantly
enriched, like “protein folding” (LEA P = 7.9×10−17), “response to
unfolded protein” (LEA P = 1.2×10−7), or “cellular protein complex
assembly” (LEA P = 8.8×10−6), as well as mitochondrial processes
like “mitochondrial transport” (LEA P = 8.2×10−6). The Mito dataset
contained significant terms related to mitochondrial function, which
were specific to this dataset: “electron transport chain” (LEA P =
 7.2×10−9) and “oxidative phosphorylation” (LEA P = 2.7×10−5). Detailed
results are provided in Table S7.
Enriched GO processes in ParkinTAP and Related PD
To identify and prioritize biologically relevant ParkinTAP candidates,
we compared the GO biological process enrichment results between
ParkinTAP and RelatedPD and identified 19 GO terms that were
significantly enriched in both datasets (classic score P≤10−3) (Table 3).
Of these, five processes were significantly enriched with both classic
and LEA scores (P≤10−3), and ParkinTAP candidates annotated to
these five processes (or their child processes) are identified in Table
S3 (columns GOComp; response to unfolded protein, mitochondrion
organization, intracellular transport, establishment of localization
in cell, cellular protein complex assembly). In addition, three of the
19 processes showed a significant LEA score (P≤10−3) in ParkinTAP:
“protein folding”, “cellular macromolecular complex assembly”, and
“cellular metabolic process”. ParkinTAP candidate proteins annotated to
protein folding and descendant processes are also identified in Table S3
(column GOComp; protein folding).
Table 3
Object ID: 10.1371/journal.pone.0078648.t003
GO biological processes enriched in ParkinTAP and RelatedPD
datasets.
GO ID GO Term Classic score (P#10−3) LEA score (P#10−3) ParkinTAP LEA
score (P#10−3) 1 GO:0071844 cellular component assembly at cellular level √ 2
GO:0071842 cellular component organization at cellular level √ 3 GO:0071840
cellular component organization or biogenesis √ 4 GO:0071841 cellular component
organization or biogenesis at cellular level √ 5 GO:0006986 response to unfolded
protein √ √ 6 GO:0019538 protein metabolic process √ 7 GO:0022607 cellular
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component assembly √ 8 GO:0044267 cellular protein metabolic process √ 9
GO:0016043 cellular component organization √ 10 GO:0007005 mitochondrion
organization √ √ 11 GO:0046907 intracellular transport √ √ 12 GO:0008152
metabolic process √ 13 GO:0051649 establishment of localization in cell √ √ 14
GO:0006457 protein folding √ √ 15 GO:0043623 cellular protein complex assembly
√ √ 16 GO:0035966 response to topologically incorrect protein √ 17 GO:0034622
cellular macromolecular complex assembly √ √ 18 GO:0044237 cellular metabolic
process √ √ 19 GO:0044085 cellular component biogenesis √
*. ParkinTAP LEA score P≤10−3, RelatedPD LEA score p>10−3.
In addition, out of the significantly enriched GO terms in RelatedPD, we
selected a set of five representative terms (GOSlimPD) (Table 4) and
identified a total of 50 ParkinTAP proteins that were annotated to any of
these five terms or to their descendants with a more specific annotation
(Table 2 and Table S3; column GOSlimPD).
Table 4
Object ID: 10.1371/journal.pone.0078648.t004
Representative GO terms for monogenic parkinsonism
(GOSlimPD).
GO ID GO Term GO:0008219 cell death GO:0031396 regulation of protein
ubiquitination GO:0006950 response to stress GO:0007005 mitochondrion
organization GO:0006914 autophagy
Analysis of functional relationships
To further prioritize ParkinTAP candidates, we assessed the functional
similarity between the candidate proteins and the proteins included
in MonogenicPD. The FunSimPDsub network (Figure 2) represents
the functional relationships between the ParkinTAP and MonogenicPD
proteins that showed a functional similarity score ≥0.7. It includes
211 proteins, 157 of them in a single connected component including
149 ParkinTAP candidates. The remaining 54 candidate proteins are
not functionally similar (functional similarity score ≥0.7) to any other
protein in FunSimPDsub. In this network, six significant protein clusters
(P≤0.05) were identified, and GO enrichment analysis was performed
for the proteins included in each cluster. Cluster 1 proteins are mainly
involved in RNA processing and translation, cluster 2 proteins are
involved in transcription, RNA processing and splicing, cluster 3
represents processes related to complex assembly, protein folding,
mitochondrion organization, and cytoskeleton-dependent intracellular
transport, proteins in cluster 4 are involved in mitochondrial processes,
like mitochondrial transport, mitochondrial ATP synthesis, and
respiratory electron transport chain, cluster 5 proteins are involved in
protein folding, and the over-represented processes in cluster 6, which
contains most MonogenicPD proteins, are related to programmed cell
death and mitochondrion organization. Detailed enrichment results for
the six protein clusters are provided in Table S8.
Figure 2
Object ID: 10.1371/journal.pone.0078648.g002
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Functional similarity network FunSimPDsub.
This network includes ParkinTAP candidates and MonogenicPD proteins
with a functional similarity score ≥0.7; six significant clusters were
identified (P≤0.05).
To better investigate which ParkinTAP candidates are functionally
related to MonogenicPD proteins, we generated the subnetwork
FunSimPD_ND1 consisting of only MonogenicPD proteins and the
ParkinTAP candidates that are functionally related to them (functional
similarity score ≥0.7) (Figure 3). FunSimPD_ND1 includes 38 proteins
in a single connected component, which were again grouped into four
significant clusters (P≤0.05) with most MonogenicPD proteins contained
in clusters 1 and 3. In cluster 1 of this network, biological processes
related to programmed cell death and mitochondrion organization
are enriched (Figure 4A), cluster 2 proteins are mostly involved in
translation and protein folding, cluster 3 proteins are enriched in
processes like programmed cell death, mitochondrion organization,
protein folding and proteolysis (Figure 4B), and cluster 4 proteins are
mainly involved in mitochondrial ATP synthesis.
Figure 3
Object ID: 10.1371/journal.pone.0078648.g003
Functional similarity network FunSimPD_ND1.
This network consists of ParkinTAP candidates that are functionally
related to MonogenicPD proteins (functional similarity score ≥0.7); four
significant clusters were identified (P≤0.05).
Figure 4
Object ID: 10.1371/journal.pone.0078648.g004
FunSimPD_ND1 clusters 1 (A) and 3 (B) with the enriched GO
processes listed in the inserted tables.
Proteins annotated to enriched processes are marked in the networks
with symbols listed in the GO enrichment tables. To remove redundancy,
enriched processes that are descendants of listed processes or that map
only to MonogenicPD proteins were excluded.
Comparison of ParkinTAP candidates to genetic
interaction screens and GWAS data
In order to further assess the biological relevance of the Parkin-
interacting proteins identified in our study, we compared our candidate
dataset with the results of a recently published genetic screen for
modifiers of Parkin and PINK1 mutant phenotypes in Drosophila
[26]. From this screen, 127 cytological regions were identified that
enhanced or suppressed the Parkin wing-posture phenotype or caused
lethality prior to adult stage. In these cytological regions, 5,420 human
orthologues were annotated and an overlap of 94 proteins with our
dataset of candidate Parkin-interacting proteins was identified (P =
 6.0×10−12 relative to the total number of human genes and P = 1.5×10−4
relative to the total number of fly genes) (Table 2 and Table S3; column
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ParkinGS). The same analysis was performed for the PINK1 mutant
phenotypes, where 97 cytological regions were identified that affected
the PINK1 wing-posture phenotype or reduced fly viability [26]. These
regions were mapped to 4,163 human orthologues, which overlap with
76 ParkinTAP candidates (P = 2.4×10−10 and P = 2.2×10−4 relative to
human genes or fly genes, respectively) (Table 2 and Table S3; column
Pink1GS).
The ParkinTAP candidates were also compared to human GWAS results
for PD to look for evidence of potential association signals in or around
the genes encoding these candidate proteins. Comparison to the PDGene
database [27] resulted in only one gene overlap (LMNA) within a
distance of 50 kb of the listed genetic variants. A variant within this
gene has been associated with PD in a recent GWA meta-analysis (P =
 2.4×10−6) [28].
Prioritization of candidate proteins
A set of criteria was defined to assign a prioritization score (selection
level) for each candidate protein, which is listed in the last column
of Table 2 (for candidates with selection level 0–7) and Table S3 (for
all candidates). The selection levels range from lowest priority level
8 to highest priority level 0. By default, the candidate proteins have
a selection level 8; if they are annotated to PD-related processes,
they are assigned to selection level 7, and if they either interact or
are functionally similar to PD-related proteins, the selection level
is 6. Candidates with the selection levels 3, 4, and 5 interact or are
functionally similar to PD-related proteins, and in addition match
candidates from the PINK1TAP screen, or are annotated to PD-related
processes, overlap with the Parkin/PINK1 fly genetic screen or do not
interact with many proteins (and therefore tend to make unique/specific
interactions). If the candidates both, interact and are functionally
similar to PD-related proteins, they are prioritized with selection level
2. Candidates that interact with more than one PD-related protein are
assigned to top rank selection level 1. Selection level 0 is reserved to
candidates that have been reported to interact with Parkin in HNet. The
criteria are outlined in the Supporting Information and visualized in an
overview graph (Figure S2).
Comparison of ParkinTAP candidates to Endeavour
Using Endeavour [29], an independent gene prioritization was
performed. In general, the genes prioritized with Endeavour are also
top ranking according to the selection levels described in the previous
section. In total, eight genes have an Endeavour prioritization score
<0.01, and seven of these genes also have a selection level ≤5. The
Endeavour results and the corresponding selection levels according to
our prioritization are provided in Table S9.
Comparison of ParkinTAP candidates to a dataset of
Parkin substrates and interactors
A recent study provided a systematic identification of Parkin-dependent
ubiquitylation targets and interacting proteins [30]. Eight out of 155
proteins reported to interact with Parkin in this study (weighted and
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normalized D-scores ≥1.0) match the ParkinTAP candidates listed in
Table S3. Parkin is one of the matching proteins, three other matching
candidates have a selection level of 3 (TOMM70A, TUBA1C, TUBA4A),
the remaining four candidates have selection levels 7 and 8 (SLC25A4,
RPS27A, TUBB7P, EEF1A2). One of these matching candidates (RPS27A)
was prioritized also by Endeavour. The overlap between the ParkinTAP
candidates and the interaction results from this study is statistically
significant (Fisher's exact test P<1×10−3). In addition, seven out of
99 Parkin ubiquitylation targets (class 1 results) are also included in
the ParkinTAP candidates from our study. Parkin is again one of the
matching candidates, two additional matching candidates have selection
level 0 (HSPA8, HSPA1A), other four have selection level 3 (TOMM70A,
HSP90AB1) or selection levels 6 and 7 (HNRNPF, YWHAE). The overlap
is again statistically significant (P<1×10−3).
Co-immunoprecipitation
For validation of candidate Parkin-binding proteins, we performed co-
immunoprecipitation experiments from HEK293T cells for the two
candidates shown in Figures 1A and 1B (LRPPRC and TOMM70A).
Figure 5 shows the results of the co-immunoprecipitation using
antibodies raised against the two candidate Parkin-interacting proteins.
We observed co-immunoprecipitation with TOMM70A, whereas the
interaction with LRPPRC seems to be non-specific as the Western Blot




Co-immunoprecipitation assays for Parkin and candidate binding
proteins.
Extracts from untransfected HEK293T cells were subjected to
immunoprecipitation with anti-Parkin or control IgG antibodies, followed
by Western Blot of input and immunoprecipitation (IP) fractions with
antibodies against LRPPRC and TOMM70A. The asterisk indicates a non-
specific band.
Discussion
Although the Parkin gene was identified 15 years ago [31], the multiple
functions of this protein and the precise mechanisms by which it exerts
its protective effect remain the subject of intense investigations. An
important step in understanding the various functions of Parkin is
placing it in a network of biochemical pathways, as the breakdown of
these cellular pathways or processes, in which a group of proteins work
together, may result in Parkin-associated pathology. To understand such
network perturbations, it is necessary to systematically explore the
complex interaction network in which the Parkin-binding proteins are
interconnected.
In this study we identified 203 candidate Parkin-binding proteins using
TAP/MS proteomic screens. The interactions between these proteins
were investigated within HNet, and most of them were part of a single
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connected component. Whereas only three candidate proteins are
known Parkin-binding proteins according to HNet (DNAJA1, HSPA1A,
HSPA8) [23], 164 interact with Parkin through one intermediate protein,
and 40 interact with one or two other proteins known to be involved
in monogenic parkinsonism, which suggests that they might function
together in a PD-specific pathway. This is supported by the finding that
proteins linked to the same disease have a high propensity to interact
with each other and that proteins in a close network-based vicinity to a
disease-related protein can therefore be expected to play a role in the
same disease-related process [32].
The biological processes enriched in the identified candidate proteins
were compared to the processes enriched in the proteins causing
monogenic forms of parkinsonism. Several processes, like protein
folding, response to unfolded proteins, mitochondrion organization,
and cellular protein complex assembly were found to be significantly
enriched in both datasets. Also in the pathway analysis, the protein-
folding pathway is enriched in the candidate proteins, and protein
processing in the endoplasmic reticulum is significantly enriched both in
the candidates and in the PD-related proteins.
By analyzing the functional similarity between the candidate proteins
and the PD-related proteins, we identified six functional groups related
to RNA processing, complex assembly, protein folding, intracellular
transport, mitochondrial transport and ATP synthesis, and programmed
cell death. These six protein clusters contained 149 candidate
Parkin-binding proteins in total. Whereas most of the candidates are
functionally similar amongst themselves, in cluster 6 the candidates
are all functionally related to the PD-related proteins, with the only
exception of YWHAE (Figure 2). A sub-network containing only the
candidate proteins that are functionally similar to the PD-related
proteins includes 37 proteins in total and 29 candidate Parkin-binding
proteins (Figure 3). Twenty-eight candidates fall into four clusters
of enriched GO processes that cover the functions of the known PD
proteins, including the various known functions of Parkin. Among these
processes we have identified several proteins involved in cell death:
HSPD1, CASP14, H1F0, DAP3, AIFM1, GSDMA, SET, OPA1, and BAG2.
In addition, TOMM70A, DAP3 and OPA1 are involved in mitochondrion
organization, and CCT3, CLPX1, HSPD1, PRKCSH and BAG2 are related
to protein folding. Of the 29 candidates that are functionally similar
to the PD-related proteins, 13 were also identified in a genetic screen
as modifiers of Parkin and PINK1 mutant functions in Drosophila
(three additional candidates were identified only as Parkin modifiers)
[26], providing further evidence for the biological relevance of the
interactions (Table 2).
The diverse functions of the Parkin protein partners reported here are
consistent with the functional diversity of the pathogenic processes
associated with Parkin-linked parkinsonism. Parkin is localized in
the endoplasmic reticulum, the Golgi apparatus, the outer nuclear
membrane, synaptic vesicles [33], [34], and the outer mitochondrial
membrane [35], and there is a large body of evidence showing
that Parkin can interfere with a diverse range of cellular processes
and pathways. Like other E3 ubiquitin ligases, it is a component of
the ubiquitin proteasome system (UPS), a main cellular pathway
that promotes removal of damaged or misfolded proteins [36], it is
Profiling of Parkin-Binding Partners 15
involved in signal transduction, protein and membrane trafficking and
transcriptional regulation [37]–[39], replication and transcription of
mitochondrial DNA [35], mitophagy [13], neuroprotection [40], and
apoptosis [41].
Parkin expression has been reported to protect cells against multiple
forms of stress [42], but although the exact mechanism of this
prosurvival function remains elusive, accumulating evidence exists that
it involves inhibition of programmed cell death (apoptosis). Two recent
studies identified Bax and the mitochondrial pro-apoptotic protein ARTS
as Parkin substrates that both might contribute to the anti-apoptotic
effect of Parkin [43], [44]. In our study, we identified novel associations
between Parkin and several proteins involved in cell death processes.
An interaction of Parkin with one of them, OPA1, is supported by the
observation that inactivation of OPA1, which promotes mitochondrial
fusion, rescues the phenotypes of cell death, muscle degeneration,
and mitochondrial abnormalities in Parkin and PINK1 mutants in
Drosophila [11]. DAP3, another candidate protein involved in cell death,
mediates mitochondrial fragmentation, probably reflecting its role in
mitochondrial fission [45]. Both proteins might have a role in cell death-
associated changes in mitochondrial morphology mediated by Parkin.
TOMM70A, which encodes a component of a translocase complex of the
outer mitochondrial membrane involved in the import of mitochondrial
precursor proteins [46], has been associated recently to Parkin as it is
degraded by the UPS after translocation of Parkin to mitochondria [47].
LRPPRC, which was identified already in a proteomic analysis of Parkin
interactors [48], might be involved in mitophagic initiation, maturation,
trafficking, and lysosomal clearance through its interaction with the
MAP1S protein [49]. Other Parkin-binding proteins, like HSPD1 and
CLPX, are involved in protein folding and response to unfolded proteins.
HSPD1 is one of the most important components of the protein folding
system within the mitochondrial matrix [50], and CLPX functions in
substrate degradation [51].
In vitro derived TAP results contain false positive interactions and do not
represent all binding proteins. Although the two sequential purification
steps of the TAP method largely reduce the background resulting from
non-specific protein binding compared to a single purification step,
these contaminants cannot be completely removed. A limitation of the
TAP/MS approach, which preferentially detects interactions within a
protein complex [52], is that it is not very powerful for the detection
of transient interactions, such as between E3 ubiquitin ligases and
their substrates. Therefore, the proteins identified in our study might
more likely be Parkin-binding partners than Parkin substrates. In this
respect, it is however reassuring that there is a statistically significant
overlap between the ParkinTAP candidates from our study and the
Parkin interactions and ubiquitylation targets reported in another recent
study [30].
Furthermore, the purification step involving the Calmodulin-binding
peptide has proven to be problematic when many proteins interact with
calmodulin in a calcium-dependent manner [53]. Candidate Parkin-
binding proteins that bind also to Calmodulin might therefore be
potential TAP artifacts (Table 2 and Table S3; CalmodulinIP). Also, the
binding peptides might disturb the function of the tagged proteins.
However, similar to untagged Parkin, TAP-tagged Parkin translocated to
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depolarized mitochondria and induced their removal, indicating that the
tag did not interfere with Parkin-mediated mitophagy (data not shown).
Protein interaction data generated by any method need to be confirmed
through experimental validation, like co-immunoprecipitation assays.
For one of two candidate proteins tested, we were able to confirm a
physical interaction with Parkin. However, whereas immunoprecipitation
gives validation of the physical interaction of proteins, genetic screens
in model organisms like Drosophila melanogaster provide additional
information about the biological relevance of the interaction of
candidate proteins and their putative role in genetic pathways related
to PD. The utility of combining protein-interaction screening with
genetic-interaction screening to validate protein-protein interaction
data was shown in a screen for huntingtin-interacting proteins [54]. In
addition, a simple comparative analysis between the candidate Parkin-
binding proteins and the results from previously published GWAS was
performed. A more extensive analysis will be the focus of future work,
in particular by considering SNPs with P-values below the reported
significance thresholds and by accounting for multiple genes that may
be in the same linkage disequilibrium block as associated variants.
Prioritization of candidate binding proteins based on functional
annotations might result in a “knowledge bias” towards well-
characterized genes. In our study, this is partially countered by also
considering previously reported protein interactions, which should not
be affected by the same type of bias. However, a careful interpretation
of the interactome results is necessary given the noise in the public
data, in particular regarding complexes, where the exact interaction
partners within the complex are unknown [55]. The network of protein
interactions involving PD-related proteins and the candidate Parkin-
binding proteins includes a relative large number of interactions within
multi-protein complexes. This effect can be quantified by measuring
the network density (ratio between the number of edges and the
theoretical maximum number of edges). For example, the network
density of the shortest path network SpNet is 3.6%. This relatively high
network density reflects the nature of the many processes involved
in PD, but it is also a result of the noise in the complex interaction
data that is magnified as a result of the matrix expansion described in
the Methods section. In this regard there have been some efforts to
annotate the reported protein interactions with reliability scores [56].
Once such reliability scores are widely available, they can be used to
filter unreliable interactions, which should result in less dense and noisy
networks.
In summary, our study has identified novel candidate Parkin-binding
proteins with diverse functions that can be associated to the many
pathogenic processes of Parkin-linked parkinsonism. The functional
diversity of the Parkin-binding proteins and their involvement in cell
death processes, protein folding and response to unfolded proteins, the
fission/fusion machinery, and the mitophagy pathway further reveals
the diversity and complexity of Parkin function and confirms the large
impact of Parkin on cellular physiology. Further studies are necessary
to generate high quality, comprehensive interaction datasets for other
PD proteins, which can be used to identify shared disease pathways
and their components. Focusing not just on individual proteins but, on
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a network of proteins will prove essential to provide new targets for the
development of therapeutic interventions.
Methods
Cell culture
In this study two cell lines were used: Human embryonic kidney cells
(HEK293T, ATCC CRL-11268) and Human neuroblastoma cells (SH-
SY5Y, ATCC CRL-2266). HEK293T were cultured in Dulbecco's modified
Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum
and 1% penicillin-streptomycin (all Lonza). SH-SY5Y, ATCC CRL-2266
were cultured in DMEM-F:12 (Lonza) supplemented with 10% fetal
bovine serum and 1% penicillin-streptomycin. Cells were maintained
at 37°C in a saturated atmosphere containing 5% CO2. To dissipate
the mitochondrial membrane potential, cells were treated with the
potassium ionophore valinomycin (1 µM, Sigma) or the protonophore m-
chlorophenylhydrazone (CCCP) (10 µM, Sigma).
Mitochondrial preparation
Mitochondria were isolated from HEK293T and SH-SY5Y cells
as previously described [57]. In brief, cells were harvested and
homogenized in buffer containing 250 mM sucrose, 10 mM Tris, 1
mM EDTA, pH 7.4 containing protease and phosphatase inhibitors
(Roche Diagnostics). In order to remove nuclei and unbroken cells,
the homogenate was centrifuged twice at 1,500×g for 10 min. The
supernatant containing intact mitochondria was transferred into a new
tube and centrifuged at 8,400×g for 10 min. The resulting supernatant
(“cytosolic fraction”) was centrifuged once again to obtain a purer
fraction (8,400×g for 10 min), whereas the mitochondria-enriched pellet
(“mitochondrial fraction”) was washed once with the buffer described
above and centrifuged at 8,400×g for 10 min.
Tandem Affinity Purification
To identify Parkin-interacting proteins, the InterPlay Mammalian
Tandem Affinity Purification (TAP) System was used according to the
manufacturer's instructions (Agilent Technologies). TAP was performed
for whole cell lysates of HEK293T cells as well as for mitochondrial
and cytosolic fractions of treated and not treated HEK293T and SH-
SY5Y cells. In brief, full-length Parkin cDNA was cloned downstream
of the multiple cloning site into the pCTAP expression vector, which
encodes two different affinity purification tags (a streptavidin and a
calmodulin binding peptide). Subsequently, 108 HEK293T and SH-
SY5Y cells were transiently transfected with the pCTAP-Parkin vector
using the CaPO4 method [58]. Whole cell and mitochondrial pellets
were resuspended in lysis buffer supplemented with protease and
phosphatase inhibitors, whereas the cytosolic fraction was already
dissolved in the buffer used for the mitochondrial preparation. Next, 2
mM EDTA, 10 mM β-mercaptoethanol, and the streptavidin resin were
added to the cell lysate and incubated at 4°C while rotating for 2 h. The
resin was collected by centrifugation (1,500×g, 5 min), washed twice
and incubated with biotin-containing streptavidin elution buffer for
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30 min at 4°C to elute the protein complexes. As a second purification
step, calmodulin resin and a calcium containing buffer were added
to the eluate and the mixture was incubated at 4°C on a rotator for
2 h. The resin was collected by centrifugation (1,500×g, 5 min) and
washed twice. Bound protein complexes were eluted using the EDTA-
containing calmodulin elution buffer for 30 min at 4°C. The final eluate
was concentrated using the ProteoExtract® Protein Precipitation Kit
(Merck Millipore), and the precipitate was sent for identification of the
unknown proteins to the Taplin Biological Mass Spectrometry Facility
(Harvard Medical School, Boston, USA). According to their guidelines,
only proteins with two or more peptide matches with the respective




Ensembl Biomart 64 [59] was used to map between Entrez Gene ID,
HGNC gene symbols and UniProtKB accession numbers. Drosophila
melanogaster genes were mapped to human orthologous using
InParanoid 7.0 [60]. All comparisons between datasets were made using
Entrez Gene IDs, except for the comparison to the genetic interaction
screen results in Drosophila, which was performed with Ensembl Gene
ID. In the following, the HGNC gene symbols are used to identify both
genes and their encoded proteins, according to the context.
Protein-protein interactions
As a source of known protein-protein interactions, iRefIndex 9.0 was
used, which combines protein interaction data from multiple primary
resources [55]. There are two types of interactions: binary interactions,
which involve two interactors, and complex interactions, which are
characterized by more than two interactors and where the pairwise
physical contacts are not specified. Both types of interactions were used
to build the network models. Protein complexes were expanded using
the matrix expansion model, where pairwise interactions are assigned
between all interactors within a complex. Data were filtered to exclude
predicted interactions, in particular interactions, for which the detection
method contained “predicted”, “interologs mapping” or “confirmational
text mining”. The resulting network was labeled “HNet”.
From this network, a shortest path network (SpNet) was derived
by selecting all proteins and interactions within the shortest paths
between the ParkinTAP candidates identified in our study and the
MonogenicPD proteins [20], the known Parkin interactors (ParkinIP) and
the MonogenicPD interactors (MonogenicPDIP) (see protein datasets
in Table 1; the proteins contained in the datasets are included in Table
S1). DAPPLE, which uses InWeb, a curated interaction network [61], was
used to assess the statistical significance of the connectivity within the
ParkinTAP candidates and the MonogenicPD proteins.
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Pathway enrichment analysis
Pathway enrichment analysis was performed with ConsensusPathDB-
human release 23 [62], which integrates different databases of human
biological processes, metabolic and signaling pathways and protein
interactions. Pathway enrichment analysis was performed for a given
protein dataset by computing a P-value for each pathway according
to the hypergeometric test and corrected for multiple testing using
the false discovery rate method (FDR). The procedure is described in
ConsensusPathDB as “over-representation analysis” on pathway-based
protein datasets.
Gene ontology enrichment analysis
Functional annotation was provided by the Gene ontology (GO) project
[63]. GO enrichment analysis was performed using topGO [64], a method
that takes into account dependencies between GO terms resulting from
the GO graph topology. Version 2.6.0 of topGO was used, as provided
with Bioconductor version 2.9. The analysis was restricted to GO
biological processes, and two different GO enrichment scores were
computed. The “classic” score is based on the standard Fisher's exact
test and is a P-value corrected for multiple testing by FDR, but it does
not take into account the GO graph structure and the children/parent
dependencies between GO terms. The “LEA” score is locally adjusted
for the dependencies between GO terms, where more generic terms
are down-weighted versus descendant (more specific) GO terms. The
GO processes are sorted by LEA score (P≤10−3), and the multiple test
corrected classic score is used to confirm the significance of the GO
terms selected with LEA.
Functional similarity
Functional similarity between proteins was computed using FunSimMat
release 4.2 as previously described [65], [66]. In particular, FunSimMat
computes a semantic measure of functional similarity based on the
GO annotation obtained from the Gene Ontology Annotation database
[67]. The analysis was restricted to biological processes. Each protein
was identified by the corresponding Entrez Gene ID, which was
mapped to UniProtKB accession numbers. In many cases, multiple
UniProtKB accession numbers were mapped to a single initial gene ID
(mapping is many to many), and in these cases the functional similarity
corresponded to the maximum functional similarity obtained for any
of the UniProtKB entries. A functional similarity network (FunSimPD)
was generated, where nodes correspond to proteins from ParkinTAP,
MonogenicPD and MonogenicPDIP datasets. Proteins were connected
by edges, if their functional similarity score was ≥0.7. From FunSimPD
two subnetworks were extracted for detailed analysis (FunSimPDsub,
FunSimPD_ND1), and distinct groups of functionally related proteins
were identified by graph clustering.
GO Slims
QuickGO [68] was used to identify proteins from a given dataset that
have been annotated with a GO term or children from a set of specific
GO terms (GO Slim).
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Network analysis and visualization
Cytoscape 2.8.1 was used for network visualization of protein-protein
interactions and functional relationships [69]. Clustering was performed
with the Cyotscape plugin ClusterONE, which can identify densely
connected overlapping regions within networks [70]. Edges weighted
according to functional similarity score were used for clustering the
functional similarity networks.
Endeavour gene prioritization
An independent gene prioritization of the candidate Parkin-binding
proteins was performed with Endeavour [29], an established
prioritization tool. Ensembl gene IDs were provided as input, the
MonogenicPD dataset was used for training, and all data sources
available in Endeavour were used for prioritization.
Co-immunoprecipitation and Western Blot
HEK293T cells were washed with ice-cold PBS, removed with a scraper,
and resuspended in lysis buffer (150 mM NaCl, 50 mm Tris-HCl, 1%
Triton X-100, and 0.1% SDS, pH 7.6). After incubation for 30 min at
4°C, insoluble material was removed by centrifugation at 14,000×g
for 10 min. Protein concentrations were determined using the Bio-Rad
DC Protein assay (Bio-Rad). The sample was precleared by incubation
with protein A Agarose beads (Roche Diagnostics) for 30 min at 4°C.
The beads were removed by centrifugation and the samples were
incubated overnight at 4° with rabbit anti-Parkin (Abcam, ab15954)
or control IgG (purified rabbit IgG, Millipore). The antigen-antibody
complexes were captured by addition of protein A Agarose for 2 h at
4°C and washed three times with wash buffer (150 mM NaCl, 50 mM
Tris-HCl, 1% Igepal, pH 7.6). Proteins were released from the beads
by heating at 95°C for 5 min in 4x Sample buffer containing DTT (Life
Technologies), followed by SDS-PAGE, blotting onto nitrocellulose
membranes, and incubation with anti-TOMM70A (Abcam, ab135602),
LRPPRC (Abcam, ab97505), and Parkin (Cell Signaling, #4211)
antibodies. Immunoreaction was visualized using the SuperSignal West
Dura Chemiluminescence Westernblot Substrate (Thermo Scientific).
Supporting Information
Figure S1
Interaction networks for ParkinTAP candidate proteins CLPX (A),
PRKCSH (B), DAP3 (C), and CALU (D). Proteins are represented
as nodes and interactions as edges; the edges are drawn as solid
and dashed lines for binary and complex interactions, respectively.
Interactions to the selected candidate proteins are represented by
thicker edges. ParkinTAP ND X are ParkinTAP candidates at network
distance X of MonogenicPD, where ParkinTAP ND 1 are direct
MonogenicPD interactors.
(TIF)
Click here for additional data file.
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Figure S2
Overview of criteria for the definition of the selection levels. The
different datasets are labeled according to the legend of Table S3. “L”
stands for selection level.
(TIF)
Click here for additional data file.
Table S1
Proteins contained in the datasets listed in   Table 1  .
(TSV)
Click here for additional data file.
Table S2
ParkinTAP proteins that do not interact with the other candidate
proteins.
(TSV)
Click here for additional data file.
Table S3
Summary table for all ParkinTAP candidate proteins.
(TSV)
Click here for additional data file.
Table S4
ConsensusPathDB enrichment results for the RelatedPD dataset.
(TSV)
Click here for additional data file.
Table S5
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